Zantac Prostate Cancer

Zantac and other ranitidine products have been withdrawn from the market by the Food and Drug Administration because of its association with NDMA (N-Nitrosodimethylamine). Prevailing scientific evidence concludes that NDMA is a probable carcinogen – or cancer-causing agent. Prostate cancer is one of the cancers associated with this dangerous contaminant.

The NDMA Basics

NDMA is an organic chemical that occurs during both natural and industrial processes. NDMA is a member of a chemical class known as nitrosamines that are considered powerful carcinogens. While NDMA is no longer produced in pure form in the United States – other than for scientific research – it was formerly used in the production of rocket fuel and lubricants. This usage was discontinued when the water, air, and soil around manufacturing plants was determined to have been contaminated. NDMA, however, can be produced unintentionally as a result of its chemical instability, which may play a role in why NDMA levels in people who regularly take ranitidine are often so elevated.

Prostate Cancer

Prostate cancer is generally a slow-growing cancer that is initially confined to the prostate gland and is one of the most common cancers in men. There are, however, more aggressive forms of prostate cancer that are far more dangerous and more difficult to treat. While men often don’t experience symptoms in the early stages of the disease, there are several symptoms associated with more advanced stages, including:

• Difficulty urinating
• A urine stream with decreased force
• Bone pain
• Discomfort in the pelvic region

Consulting with an Experienced Drug Injury Attorney Can Help

If you have concerns related to Zantac usage and a prostate cancer diagnosis, don’t put off consulting with a dedicated drug injury lawyer. Your rights and your rightful compensation are far too important to leave to chance.